Faculty
Assistant Professor of Medicine at Rush University Medical Center,
Division of Hematology/Oncology and Stem Cell Transplant
Director, Coleman Foundation Comprehensive Multiple Myeloma Clinic
Rush University Medical Center
Chicago, ILAgne Paner, MD has disclosed having the following financial arrangements or affiliations with the commercial interests listed below whose products or services may be mentioned in this activity.
Advisory Board: Takeda Oncology
Member, Speakers’ Bureau: Celgene, Onyx/Amgen
Consultant: Takeda Oncology
Kimberly Lynch
Planner/Manager
PleXus Communications
Kim Lynch has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.
Michaela Ryan, PhD
PleXus Communications
Michaela Ryan, PhD has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.
Accredited By
Rush University Medical Center
Co-provided By
Activity Details
0.25 Contact Hour(s)
Expires: December 20, 2018
Goals (Purpose) of Program
To provide learners with a greater ability to formulate optimal evidence-based strategies for the individualized treatment of their patients with multiple myeloma.
Learning Objectives
At the completion of this module, participants should be able to:
- Formulate criteria for identifying and managing smoldering multiple myeloma, including when to initiate treatments
- Describe the clinical course and prognosis of smoldering asymptomatic multiple myeloma
- Identify promising biomarkers in multiple myeloma
Target Audience
This activity is designed to meet the needs of healthcare professionals involved in the treatment of patients with multiple myeloma.
Conflict of Interest Policy/Disclosure Statement
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.
Rush University Medical Center designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours.
Rush University Medical Center designates this knowledge-based CPE activity 0622-0000-17-057-H01-P for 0.25 contact hours for pharmacists.
This activity is being presented without bias and with commercial support.
Requirements for Successful Completion
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Instructions for Receiving Credit
Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 2 out of 3 or better. Certificates will be generated upon completion and submission of the evaluation form.
Statement of Commercial Support
This activity is supported by an educational grant from AbbVie, Amgen, Celgene Corporation, Incyte Corporation, Janssen Biotech, Inc., and Merck.
Disclaimer Statement/Disclosure of Unlabeled Use
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Contact Information for Questions about the Activity
Info@plexuscomm.com
866-607-4333